Pulmonology

They were also 3 times more likely to suffer from cancer, and reported a greater rate of hypertension and cardiovascular disease.

Last week in Nature, data were published revealing that AD-114, a locally developed molecule, could be a therapeutic option for patients with idiopathic pulmonary fibrosis.

New data from the US Centers for Disease Control and Prevention show that robust asthma education and prevention programs are working.

The American Lung Association will host two events this spring: the 2018 Greater Philadelphia LUNG FORCE Expo and a webinar for sarcoidosis patients focusing on improving health outcomes and support programs.

Roughly 41% of those diagnosed with psychiatric illness were also smokers, and they were 70% more likely to be smokers than their counterparts without psychiatric illness.

Among new users of LABA and LAMA, treatment was associated with a 1.50-fold and a 1.52-fold increase in CVD risk, respectively.

Arrowhead Pharmaceuticals Inc. announced that the company’s second-generation investigational medicine ARO-AAT was granted orphan drug designation by the FDA.

The chances of getting pregnant for current asthmatics who managed their symptoms with SABAs was 15% lower when compared to non-asthmatics.

A 20-year study of over 6000 European participants found reason to be concerned over the harm of cleaning chemicals.

When patients are given comprehensive education, have medications in hand, and have a follow-up appointment scheduled at discharge, they’re less likely to be readmitted to the hospital.

A new study finds tighter fuel standards for ships will have a major impact on public health globally.

The guidelines were created by Vanderbilt’s Asthma Steering Committee and implemented in May 2014.

Data published in The Orphanet Journal of Rare Diseases confirmed that currently-available enzyme replacement therapies are unable to reverse or stabilize the progression of Pompe disease.

The U.S. FDA approved tezacaftor/ivacaftor and ivacaftor (Symdeko) for the treatment of the underlying cause of cystic fibrosis in people ages 12 years and older who have 2 copies of the F508del mutation.